Introduction
Bovine papillomavirus type 4 (BPV-4) induces papillomas in the mucosal epithelium of the upper gastrointestinal tract of cattle ; the papillomas can undergo neoplastic progression if stimulated by the appropriate cofactors present in bracken fern . Although its genome organization is similar to that of other papillomaviruses, BPV-4, like the closely related BPV-3 and BPV-6, lacks the E6 ORF (Jackson et al., 1991) , which is found in all other characterized papillomaviruses (Giri & Danos, 1986) . In human papillomavirus (HPV) the E6 ORF encodes a small acidic protein of approximately 150 amino acids, which is capable of cell immortalization on its own, but requires the cooperation of another viral oncoprotein, E7, in order to fully transform cells (Munger et al., 1992) . The transformation properties of E6 are mediated by four C-X-X-C motifs which form two zinc finger domains (Barbosa et al., 1989) and by the domains which bind and degrade the cellular tumour suppressor protein p53 (Scheffner et al., 1990) . There is a direct relationship of the binding affinity of E6 for p53 and its ability to promote degradation of the protein with the cell transformation potential of the virus. Thus, the E6 protein of ' high risk ' HPVs associated with genital cancer, such as HPV-16 and -18, efficiently binds and degrades p53, while E6 of ' low risk ' viruses, such as HPV-6 and -11, binds p53 with lower affinity and does not facilitate its degradation . The abrogation of the tumour suppressing function of p53 by E6 does, therefore, appear to be instrumental in neoplastic progression. It has been reported that in cervical cancer cell 0001-4953 # 1997 SGM lines expressing HPV E6, the p53 gene was not mutated, while in similar lines devoid of HPV E6 the p53 gene had undergone mutation, stressing the importance of the removal of p53 function in carcinogenesis, either by E6-mediated degradation or by mutations (Crook et al., 1991 b) . However, analysis of primary cervical cancers has identified HPV-positive cancers with a mutated p53 gene, and conversely, HPV-negative cancers with a wild-type p53 gene (Fujita et al., 1992 ; Choo & Chong, 1993) . The relationship between HPV E6 and p53 is therefore more complex than first thought. Given the role of the E6 protein in cell transformation, the lack of an E6 ORF in the genome of BPV-4 raises questions of whether p53 inactivation is important in BPV-4-associated carcinogenesis, whether the virus has evolved other mechanisms of evading p53-mediated growth suppression, or whether p53 is made dysfunctional by the chemical cocarcinogens present in bracken.
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To answer these questions, we have investigated the possible contributions of HPV-16 E6 (16E6) and mutant p53 to in vitro cell transformation by BPV-4 in primary bovine foetal fibroblasts (PalFs) and p53-null mouse fibroblasts. We show that both 16E6 and mutant p53 are required for oncogenic transformation of PalF cells, that 16E6 contributes to BPV-4 transformation of p53-null fibroblasts, and that therefore 16E6 provides transforming functions in addition to the binding and degradation of p53.
Methods
Plasmids. pT24, pZipneo and pBPV-4 have been described previously (Jaggar et al., 1990) . pJ4Ω 16E6 has been described by Storey et al. (1988) . pC53-SCX3, containing a mutant p53 cDNA isolated from a human colorectal tumour, and pC53-SN3, containing a wild-type p53 cDNA (Baker et al., 1990) , were a kind gift from B. Vogelstein (The John Hopkins University School of Medicine, Baltimore, Md., USA). pBabeHygro was a gift from S. Barnett (University of Glasgow, UK).
Cell culture. PalF cells were grown as described by Jaggar et al. (1990) . DNA transfection was performed using the calcium phosphate technique. Cells were selected in medium containing 500 µg\ml G418 for 21-28 days. G418-resistant colonies were scored and either ring-cloned for expansion or fixed in methanol and stained with 10 % Giemsa stain for counting. The cells were deemed to be immortal if still viable after 6 months of continuous passage.
p53-null mouse fibroblasts were derived from 2-week-old p53 knockout mice (Donehower et al., 1992) . Cells were grown, subcultured and transfected as described above for PalF cells. Transformants were selected in medium containing 125 µg\ml hygromycin B for 15-21 days. Hygromycin-resistant colonies were treated as described for PalF cells.
Anchorage-independent growth in Methocel. Cells were counted and 2i10& viable cells added to 15 ml of 10 % Methocel medium. Colonies were counted and photographed after 10-14 days.
RNA extraction from cell lines. RNA was extracted by the use of RNAzol (Cinna Biotech) according to the manufacturer's instructions.
Tumorigenicity in nude mice. 3i10( Cells were resuspended in 300 µl of PBS. One hundred µl of the cell suspension was inoculated into athymic nude mice at a single injection site. A minimum of three cell lines per transfectant category were used in tumorigenicity assays and a minimum of two mice were inoculated with each cell line. Untransformed PalF cells were tested twice. The mice were checked weekly ; animals with no tumours after 12 weeks were considered tumour-free ; animals in which tumours arose were scored as positive if the tumours persisted for longer than 12 weeks. The tumours were excised and either placed in formalin for paraffin-embedding or frozen immediately in liquid nitrogen. The mice were handled in full compliance with the regulations of the Home Office of Great Britain.
Northern blot hybridization. Northern blotting was carried out with 20 µg of total cellular RNA. The RNA was denatured at 65 mC for 15 min and electrophoresed in 1n25 % agarose gel containing 5 % formaldehyde. The gel was blotted on a Hybond-Nj membrane in 20i SSC overnight. After UV crosslinking, the membrane was incubated with salmon sperm DNA and the appropriate radioactive [$#P]DNA probe overnight at 42 mC in 5i SSC, 5i Denhardt's solution, 50 % (v\v) deionized formamide. The membrane was extensively washed in 2i SSC, 0n1 % SDS at room temperature and exposed to an XR-OMAT fast film.
Immunocytochemistry. Tumour sections were stained using the Vectastain ABC kit (Vector Laboratories) according to the manufacturer's instructions with the following modifications : antigen retrieval was carried out by trypsinizing the sections in 0n1% (w\v) trypsin, 0n1% (w\v) CaCl # in TBS, or by microwaving them in citrate buffer (0n01 M citric acid pH 6n0) before blocking the sections with normal goat serum for 30 min at room temperature. Sections were incubated overnight at 4 mC with the primary antibody. Peroxidase-conjugated anti-rabbit IgG secondary antibody was added for 30 min at room temperature and diaminobenzidine (DAB) was used to visualize the reaction. Sections were then counterstained with the blue nuclear stain haematoxylin.
CM-1 p53 antibody was used at the concentration recommended by the manufacturer (Biogenex) ; anti-E7 antiserum was raised in rabbits against multiple overlapping synthetic oligopeptides spanning the whole amino acid sequence of E7 (Chandrachud et al., 1994) and was used at 1\200 dilution ; anti-E8 antiserum was also raised in rabbits against a synthetic oligopeptide from the carboxyl terminus of E8, conjugated to keyhole limpet haemocyanin (Pennie et al., 1993) and used at 1\2000 dilution in 0n1 % BSA in PBS pH 7n6.
In situ hybridization. The whole BPV-4 genomic insert in pBPV-4 was excised from the vector using BamHI and 500 ng DNA was labelled with digoxigenin-11-dUTP (DIG) according to the manufacturer's instructions for in situ hybridization. Hybridization was carried out as described by Gaukroger et al. (1991) . The DIG detection reaction was carried out according to the manufacturer's instructions with a 1\200 dilution of the anti-DIG antibody, conjugated to alkaline phosphatase. The sections were then counterstained with 5 % aqueous eosin and mounted in a permanent water mount.
Results

Exogenous mutant p53 and 16E6 synergize with BPV-4 in PalF transformation
Mutant (V143A) p53 cDNA, isolated from a human colorectal tumour (Baker et al., 1990) , was used in transformation assays of PalF cells with BPV-4 DNA and 16E6 (Table 1) . As reported before, BPV-4 DNA can morphologically transform these cells only in the presence of an activated ras gene (Jaggar et al., 1990) , and the latter was therefore included in all transfection experiments, unless specified to the contrary, together with a neomycin-resistance gene carried in pZipneo ; transfected cells were selected with G418.
In accordance with previous results, in the presence of activated ras, transfection of BPV-4 DNA resulted in a small number of morphologically transformed colonies which were capable of anchorage-independent growth but neither immortal nor tumorigenic. The resulting cell lines were defined as PFA. Co-transfection with 16E6 ORF increased the number of transformed colonies and conferred immortality, suggesting that 16E6 can inactivate wild-type endogenous p53 (Table 1 ; Pennie et al., 1993) . These lines (termed PFB) were not tumorigenic.
Transfection of mutant p53 cDNA induced morphological transformation and anchorage independence, but the resulting cell lines (termed PFC) were not immortal or tumorigenic. In contrast, co-transfection with mutant p53 cDNA and BPV-4 DNA induced a higher number of colonies and the resulting cell lines, defined as PFD, were immortal. Therefore both 16E6 and mutant p53 can independently cooperate with BPV-4 in PalF cell immortalization. However, none of these lines was tumorigenic (Table 1) .
Co-transfection with BPV-4 DNA, 16E6 and mutant p53 cDNA resulted in a significantly higher number of transformed colonies. Four of the resulting lines, termed PFF clones a-d, were tested for tumorigenicity and all were capable of inducing tumours in nude mice (Table 1) No colonies were established from cells transfected with wild-type p53 cDNA (termed PFG), regardless of the other oncogenes present, or from cells transfected with pZipneo alone (not shown).
Expression of BPV-4 oncoproteins in transformed lines and tumours
The transformed cell lines were analysed by Northern blot hybridization for the presence of viral E7 and E8 mRNAs and p53 mRNA. Selected cell lines are shown in Fig. 1 . The 3n6 kb precursor RNA (Campo & Jarrett, 1987) was detected in all cell lines. The 2n8 kb E8 mRNA was detected strongly in two of the tumorigenic PFF cell lines, b and c (Fig. 1 A) and very faintly in the other two clones (not visible in Fig. 1 ). The 1n6 kb E7 mRNA was detected in all transformed cell lines with approximately the same intensity (Fig. 1 B) . p53 transcripts were detected by a mutant p53 cDNA probe only in cell lines transfected with the mutant p53 cDNA (Fig. 1 C) , suggesting that endogenous wild-type p53 is not detected by the heterologous human probe.
The tumours arising from PFF clones b and c were analysed immunohistochemically for the viral oncoproteins and p53, and by in situ hybridization for viral DNA. E7 was detected in the cytoplasm and in a few nuclei (Fig. 2 A) , whereas E8 was detected only as a cytoplasmic antigen (Fig. 2 B) , which is in accordance with the previously reported localization of the viral oncoproteins in bovine papillomas and in transformed cells (Anderson et al., 1997 ; Pennie et al., 1993) . p53 was detected in the nucleus of all cells (Fig. 2 C) . The signals were absent when the primary antisera were preincubated with the corresponding antigens (Fig. 2 A, B) , or when the sections were incubated with pre-immune serum (Fig. 2 C) , indicating the specificity of the reactions. No viral DNA could be detected in the tumours by in situ hybridization, whereas viral DNA was easily detected in a stage 1 papilloma (Fig. 2 D) . The sensitivity of in situ hybridization is limited by the copy number of viral genomes per cell, and the lack of detection of viral DNA in the tumours suggests that very few genomes are present.
Transformation of p53-null mouse fibroblasts by BPV-4 and 16E6
To establish the role of p53 in BPV-4 transformation and to ascertain if 16E6 was capable of cooperating with BPV-4 oncoproteins in the absence of a functional p53 gene, p53-null mouse fibroblasts (Donehower et al., 1992) were transfected with combinations of BPV-4 and 16E6 (Table 2) .
Transfection of either BPV-4 DNA or 16E6 ORF resulted in transformed colonies, but cells transfected with 16E6 ORF alone had a much flatter appearance than those transfected with BPV-4 DNA (Fig. 3) . Co-transfection of BPV-4 DNA and DAAF 16E6 ORF produced four-to sixfold as many colonies, which appeared more transformed than either alone, confirming the cooperation between BPV-4 oncoproteins and 16E6 (Table 2 ; Fig. 3 ). The addition of the activated ras gene did not make any significant difference (data not shown).
Colonies were picked and analysed for their ability to grow independently of substratum. Transfectants containing BPV-4 DNA or 16E6 ORF on their own were not capable of anchorage-independent growth, but double transfectants did grow in semi-solid media, again confirming the cooperation between BPV-4 oncoproteins and 16E6 even in the complete absence of functional p53, and therefore the ability of 16E6 to execute some functions independently from, and in addition to, sequestration of p53. The addition of activated ras did not make any significant difference (Table 2 ).
Discussion
Contribution of mutant p53 to BPV-4 transformation of PalF cells
The lack of an E6 ORF in the BPV-4 genome raises the question of how this papillomavirus overcomes the cell growth control imposed by p53. We have already shown that, in the context of activated ras, the addition of the exogenous 16E6 protein confers immortality to primary PalF cells transformed by the BPV-4 oncogenes (Pennie et al., 1993) . The same effect is achieved by replacing E6 with mutant p53, in agreement with the results of Sedman et al. (1992) , who have shown that the same p53 mutant (V143A) used in our study can substitute for 16E6 in the immortalization of human keratinocytes. Thus, dysfunction of p53, either through interactions with E6, or due to mutations, is pivotal in the induction of the immortal phenotype.
Despite their interchangeability in immortalization assays, both mutant p53 and E6 are necessary for fully oncogenic transformation of PalF cells, suggesting that BPV-4 lacks more than one function required for neoplastic progression in vitro. Previously, oncogenic in vitro transformation has been achieved only when the cells had been treated with quercetin, one of the mutagens present in bracken fern (Pennie & Campo, 1992 ; Cairney & Campo, 1995) . It would appear that dysfunction of p53, either through mutation or through the action of quercetin (Scobie, 1996 ; Avila et al., 1994 ; Plaumann et al., 1996) , is necessary for tumorigenicity of BPV-4 in vitro transformed cells. The bovine p53 gene (Coggins et al., 1995) is mutated in papillomas and carcinomas of cattle and in quercetin-treated PalF cells (Scobie, 1996) , supporting the notion that p53 functions have to be abrogated by factors other than viral E6 for full cell transformation to take place either in vivo or in vitro.
All transformed cell lines express viral RNA. E8 mRNA is expressed only in the tumorigenic PFF lines (albeit very weakly in two of the clones) suggesting that E8 expression is important for tumorigenesis. While E7 is the main transforming gene of BPV-4 in primary bovine cells, E8 provides significant contributions to cell transformation : it allows cells to grow independently of substrate (Pennie et al., 1993) and external mitogens (V. O'Brien & M. S. Campo, unpublished results), binds to 16 kDa ductin and downregulates gap junction intercellular communications (Faccini et al., 1996) . Both oncoproteins were expressed in the tumours examined, indicating their role in driving the first stages of carcinogenesis, whereas viral DNA and viral oncoproteins appear not to be required at later stages (Campo et al., 1985 ; Gaukroger et al., 1991) . E8 was detected as a cytoplasmic antigen and E7 both as a nuclear and a cytoplasmic antigen, as previously reported for naturally occurring papillomas and for in vitro transformed cells (Pennie et al., 1993 ; Anderson et al., 1997) . The nuclear localization of BPV-4 E7 is consonant with the recognized function of HPV E7 proteins of binding p105Rb and abrogating its functions (Munger et al., 1989) but, as discussed before (Anderson et al., 1997) , the function, if any, of the cytoplasmic form of BPV-4 E7 is not known. A recent report describes E7 in the nucleolus (Zatsepina et al., 1997) , confirming the ubiquitous location of E7.
BPV-4 transformation of p53-null cells
Morphological transformation of p53-null cells was achieved by BPV-4 in the absence of an activated ras gene, pointing to the need for the abrogation of p53 functions for the transformation potential of BPV-4 to be revealed. This is in accordance with the ability of BPV-4 to transform established NIH3T3 and C127 cells without the aid of activated ras (Campo & Spandidos, 1983 ; Smith & Campo, 1988) . Alternatively, the endogenous mouse ras gene may have already been inactivated as it is known that only approximately one-third of p53-null cells contain a normal karyotype, while the remaining two-thirds can become aneuploid after few passages in culture (Harvey et al., 1993) .
Although morphologically transformed by BPV-4, the p53-null cells are not capable of anchorage-independent growth. This is surprising as other cells transformed by BPV-4, whether originally primary cells or established lines, can grow independently of substrate by virtue of E8 (Pennie et al., 1993 ; V. O'Brien & M. S. Campo, unpublished results) . Anchorageindependent growth is conferred by 16E6, again confirming that 16E6 can execute functions which are independent of a functional p53.
In conclusion, BPV-4 lacks several functions needed for full in vitro transformation of primary cells. These functions can be provided by activated ras, dysfunctional p53 and 16E6. It is interesting to note that in naturally occurring bovine alimentary cancers, ras is activated and p53 is mutated (Campo et al., 1990 ; Scobie, 1996) , and that in vitro transformed cells are made immortal by quercetin treatment (Pennie & Campo, 1992 ; Cairney & Campo, 1995) . Together, these observations strongly suggest that, during neoplastic progression in vivo, DAAG functions not encoded by the BPV-4 genome are supplied by the mutagens present in bracken fern, the environmental cofactors of the virus .
